Vicore Pharma Holding AB (publ) (VCRE)

NASDAQ: VCRE · USD

$9.57

+0.22 (+2.3%)· Recorded snapshot

Market cap	275.7M
Revenue (ttm)	412.1K
Net income (ttm)	-51.8M
EPS (ttm)	-$1.92
Shares out	281.5M
Volume	14,360
Beta	0.09

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 412.1K
Net income (ttm): -51.8M
EPS (ttm): -$1.92
Market cap: 275.7M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	보유

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-57

P25 n/aP50 n/aP75 n/a

ROIC-37.2

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All VCRE indicators

Market & fundamental data

Available fields

161

Groups with data

Currency

SEK

Showing 161 of 161 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0002124403
Company name	Vicore Pharma Holding AB (publ)
Country	Sweden
Country code	US
CUSIP number	92581R104
Earnings date	2026-11-05
Employees	46
Employees change	13
Employees growth	39.39%
Enterprise value	$184.5M
Exchange	NASDAQ
Financial currency	SEK
Financial report date	2026-06-30
First seen	2026-07-12
Fiscal year end	December
Founded	2000
Industry	Biotechnology
Is primary listing	No
Is SPAC	No
ISIN number	US92581R1041
Last earnings date	2026-08-21
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$275.7M
Market cap category	Micro-Cap
Next earnings date	2026-11-05
Options	No
Price	$9.57
Price currency	USD
Sector	Healthcare
Stock price date	2026-10-28
Symbol	VCRE
Website	https://www.vicorepharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-20.08%
EV/Sales	432.7x
FCF / EV yield	-25.81%
FCF yield	-17.08%
Forward EV/Sales	1,132.12x
Forward P/S	1,710.84x
P/B ratio	3.06x
P/S ratio	653.89x
Price / tangible book value	3.06x
Sector forward P/E	23.53x
Sector P/E	51.01x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	100%
Operating margin	-13,116.96%
Pretax margin	-12,563.26%
Profit per employee	$-1.1M
Revenue per employee	$8,959
ROA	-34.35%
ROA (5Y)	-34.77%
ROCE	-61.14%
ROE	-56.99%
ROE (5Y)	-62.78%
ROIC	-37.17%
Tax / revenue	6.48%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	0
Gross profit growth	-48.4%
Gross profit growth (Q)	26.75%
Net income growth years	0
Revenue growth	-48.41%
Revenue growth (Q)	26.75%
Revenue growth (QoQ)	267.61%
Revenue growth 10Y	16.24%
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
EBIT	$-54.1M
EPS	$-1.92
FCF per share	$-0.16
Financing cash flow	$44.4M
Free cash flow	$-46M
Gross profit	$412,092
Income taxes	$26,723
Investing cash flow	$10.3M
Net cash flow	$7.9M
Net income	$-51.8M
Operating income	$-54.1M
Revenue	$412,092

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$0.31
Debt / equity	0
Long-term assets	$2.6M
Long-term liabilities	$506,295
Net cash (debt)	$93.4M
Net cash / market cap	34.68%
Net cash growth	-3.34%
Net debt / equity	-1.06
Piotroski F-Score	1
Shareholders' equity	$88.1M
Tangible book value	$88.1M
Tangible book value per share	$0.31
Total assets	$95.9M
Total cash	$93.4M
Total debt	$0
Total liabilities	$7.9M
WACC	4.75%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0
Current assets	$93.3M
Current liabilities	$7.4M
Current ratio	12.68
Net working capital	$-5.4M
Quick ratio	12.5
Working capital	$88M
Working capital turnover	0

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-32.83%
Dividend yield	0%
Shareholder yield	-32.83%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1D price change	2.3%
1M price change	-0.52%
1M total return	-0.52%
1W price change	6.67%
1W total return	6.67%
20-day SMA	$9.18
3M price change	-13.2%
3M total return	-13.2%
50-day SMA	$10.23
52-week high	$17.80
52-week high date	2026-07-07
52-week low	$7.88
52-week low date	2026-10-07
All-time high	$17.80
All-time high date	2026-07-07
All-time low	$7.88
All-time low date	2026-10-07
Average true range (ATR)	$0.67
Average volume	26.3K
Beta (5Y)	0.09
Change from 52-week high	-46.26%
Change from 52-week low	21.38%
Change from all-time high	-46.07%
Change from all-time low	21.83%
Change from open	-0.67%
Day's gap	2.99%
Dollar volume	$137,353
High price	$9.63
Low price	$9.57
Monthly RSI	0
Open price	$9.63
Position in 52-week range	0%
Premarket change	2.14%
Premarket close	$9.35
Premarket price	$9.55
Premarket volume	196
Previous close	$9.35
Price vs 20-day SMA	4.63%
Price vs 50-day SMA	-6.14%
Relative volume	0.55
RSI	50.01
Sharpe ratio	-3.06
Sortino ratio	-3.67
Volume	14.4K
Weekly RSI	30.55

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	200.8M
Float percentage	71.33%
Shares change (QoQ)	0%
Shares change (YoY)	32.83%
Shares held by insiders	4.89%
Shares held by institutions	33.51%
Shares outstanding	281.5M
Short % of float	0%
Short % of shares	0%
Short ratio	0.1 days

Deeper analysis on VCRE

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this VCRE report

Is a complete VCRE research report available?

No complete published report is available for Vicore Pharma Holding AB (publ) (VCRE) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Vicore Pharma Holding AB (publ) (VCRE)

Price

Financial snapshot

Fair-value bridge

Latest news · VCRE

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All VCRE indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on VCRE

Frequently asked questions